| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/05/2007 | CN100334964C Probiotic delivery system |
| 09/04/2007 | US7265227 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 09/04/2007 | US7265226 Interact with opoid receptors; decreasing metabolic rates of the phenolic piperidines by amidation, imidation, or forming a formamide, a hydroxyamidine or a thioamide; analgesics, anticonvulsants, antitussive agents; diarrhea, drug addiction |
| 09/04/2007 | US7265221 Pyrrolo[2,3-d]pyrimidine compounds |
| 09/04/2007 | US7265208 Autoimmune disease; allergies vaccine |
| 09/04/2007 | US7265156 Medicinal association of a biguanine and a carrier, for example metformin and arginine |
| 09/04/2007 | US7265146 Administering small molecule compounds, especially acids or esters, that inhibit the interaction between alpha 4 integrins and ligands MAdCAM and/or VCAM for treatment of chronic inflammatory diseases such as arthritis, asthma, multiple sclerosis, Chrohn's disease, ulcerative colitis, and hepatitis C |
| 09/04/2007 | US7265144 Mixture with other active materials; controlling glucose metabolism |
| 09/04/2007 | US7265139 RXR activating molecules |
| 09/04/2007 | US7265137 Phenylacetic acid derivative; hypoglycemic agents; antilipemic agents; anticholesterol agents; cardiovascular disorders |
| 09/04/2007 | US7265132 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 09/04/2007 | US7265131 For therapy of disease-states associated with nuclear receptor activity |
| 09/04/2007 | US7265130 anti-obestic activity; Neuropeptide Y antagonist |
| 09/04/2007 | US7265127 Imidazo[1,2-a]pyridine derivatives, especially N-(2-(8-(3-aminocarbonyl-2-pyridyloxy)imidazo[1,2-a]pyrid-3-yl)-1,1-dimethylethyl)-3-(o-isoxazol-3-ylphenoxy)-2-hydroxypropylamine; treating type-2 diabetes and obesity |
| 09/04/2007 | US7265125 4-Heteroaminoquinazoline derivatives,.e.g., 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinazoline; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 09/04/2007 | US7265119 For therapy of nicotine dependency |
| 09/04/2007 | US7265116 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease |
| 09/04/2007 | US7265113 Anticancer agents; antiinflammatory agents, for therapy of rheumatoid arthritis |
| 09/04/2007 | US7265111 inhibitors of lipolysis, as cardioprotective agents or they may be of value in the therapy of diabetes |
| 09/04/2007 | US7265108 For example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders |
| 09/04/2007 | US7265103 For therapy of depression, anxiety and body weight disorders |
| 09/04/2007 | US7265087 Exendin improves β-cell response in subjects with impaired glucose tolerance |
| 09/04/2007 | US7264928 whereby a DNA sample is tested for the presence of polymorphic allele; solid phase synthesis |
| 09/04/2007 | US7264813 Therapeutic uses of Dunaliella powder |
| 09/04/2007 | CA2444554C Pharmaceutical compositions of amlodipine and atorvastatin |
| 09/04/2007 | CA2397828C Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 09/04/2007 | CA2215329C Colorectal chemoprotective composition and method for preventing colorectal cancer |
| 09/04/2007 | CA2116238C Oral 1 .alpha.-hydroxyprevitamin d |
| 08/30/2007 | WO2007098504A1 Prodrugs of curcumin analogs |
| 08/30/2007 | WO2007098240A2 Compositions to reduce blood glucose levels and treat diabetes |
| 08/30/2007 | WO2007098106A2 Respiratory tract delivery of interferon-tau |
| 08/30/2007 | WO2007097707A1 Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives |
| 08/30/2007 | WO2007097315A1 Enteric gelatinous nutrient and method of preparing the same |
| 08/30/2007 | WO2007096643A1 Tea |
| 08/30/2007 | WO2007096588A1 Salt of cd 80 antagonist |
| 08/30/2007 | WO2007096251A1 Inhibitors of cpt in the central nervous system as antidiabetic and/or anti-obesity drugs |
| 08/30/2007 | WO2007096239A1 Appetite suppressant compositions |
| 08/30/2007 | WO2007096186A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| 08/30/2007 | WO2007096078A1 Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
| 08/30/2007 | WO2007095760A1 Cleavable carnitine compound |
| 08/30/2007 | WO2007095737A1 Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
| 08/30/2007 | WO2007075833A3 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| 08/30/2007 | WO2007065539A8 Extracts of gynostemma and compositions for reducing blood lipid levels |
| 08/30/2007 | WO2007063363A3 Method for determining the concentration of the adipocytic form of the fatty acid binding protein (a-fabp, fabp4, p2) |
| 08/30/2007 | WO2006127503A3 Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| 08/30/2007 | US20070203337 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase |
| 08/30/2007 | US20070203199 Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| 08/30/2007 | US20070203198 Pioglitazone insulin sensitivity enhancer with the antidiabetic glimepiride; difference in mechanism of action avoids adverse reactions over long term use; oral dosage tablet; lactose excipient, hydroxypropylcellulose binder, magnesium stearate lubricant, calcium carbonate disintegrator; diabetes |
| 08/30/2007 | US20070203184 Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them |
| 08/30/2007 | US20070203152 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 08/30/2007 | US20070203151 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 08/30/2007 | US20070203150 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 08/30/2007 | US20070203141 Method for administering birb 796 bs |
| 08/30/2007 | US20070203068 Stimulation of beta cell proliferation |
| 08/30/2007 | US20070203063 Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altererd pharmacological properties |
| 08/30/2007 | US20070203061 Adiponectin expression-inducing agents and uses thereof |
| 08/30/2007 | US20070202198 Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ROS scavengers, photo-protectors, biosensors biofilters and bioreactors |
| 08/30/2007 | US20070202181 Low hygroscopic aripipazole drug substance and processes for the preparation thereof |
| 08/30/2007 | US20070202160 Solid-state form of celecoxib having enhanced bioavailability |
| 08/30/2007 | US20070202100 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 08/30/2007 | US20070202099 Antibody Drug |
| 08/30/2007 | DE102005055726A1 Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Hydroxy-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 08/30/2007 | CA2664982A1 Cleavable carnitine compound |
| 08/30/2007 | CA2643668A1 Salt of cd 80 antagonist |
| 08/30/2007 | CA2643464A1 A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| 08/30/2007 | CA2643299A1 Compositions to reduce blood glucose levels and treat diabetes |
| 08/30/2007 | CA2638124A1 Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives |
| 08/29/2007 | EP1826218A1 Antihuman baff antibody |
| 08/29/2007 | EP1826217A1 Method for identification of antigenic peptides |
| 08/29/2007 | EP1826216A1 Glp-1 derivatives |
| 08/29/2007 | EP1826201A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| 08/29/2007 | EP1826197A1 Aminocarboxylic acid derivative and medicinal use thereof |
| 08/29/2007 | EP1825854A1 MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR |
| 08/29/2007 | EP1825851A2 Combination therapy for effecting weight loss and treating obesity |
| 08/29/2007 | EP1825850A1 Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
| 08/29/2007 | EP1825847A2 Fluvastatin sodium pharmaceutical compositions |
| 08/29/2007 | EP1824842A2 Inhibitors of 11- hydroxyl steroid dehydrogenase type 1 and methods of using the same |
| 08/29/2007 | EP1824835A1 Heteroaromatic glucokinase activators |
| 08/29/2007 | EP1824501A1 Protein hydrolysate with antidiabetic effect |
| 08/29/2007 | EP1824484A1 Drugs and prodrugs useful for the treatment of energy balance in ruminants |
| 08/29/2007 | EP1824475A1 Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol |
| 08/29/2007 | EP1824469A1 A method of modulating b cell functioning |
| 08/29/2007 | EP1824468A2 Glycogen synthase kinase-3 inhibitors |
| 08/29/2007 | EP1558615B1 Purine compounds and use thereof as cannabinoid receptor ligands |
| 08/29/2007 | EP1425019B1 Pharmaceutical composition comprising an androgen |
| 08/29/2007 | EP1414961B1 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 08/29/2007 | EP1351934B1 Naphthalene derivatives which bind to the ep4 receptor |
| 08/29/2007 | EP1333840B9 M. tuberculosis chaperonin 60.1 and uses thereof |
| 08/29/2007 | EP1165781B1 Protease resistant flint analogs |
| 08/29/2007 | EP1096932B1 Antihypertensive combination of valsartan and calcium channel blocker |
| 08/29/2007 | CN101027286A Indozolone derivatives as 11b-HSD1 inhibitors |
| 08/29/2007 | CN101027282A Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| 08/29/2007 | CN101027087A Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 08/29/2007 | CN101027063A Preventive and/or therapeutic agent for calcipenia |
| 08/29/2007 | CN101024628A Aza-flavones, its preparing method and use |
| 08/29/2007 | CN101024627A Nitrogen-containing aromatic derivatives |
| 08/29/2007 | CN101024052A Oral medicine composition for treating diabetes |
| 08/29/2007 | CN101024046A Navel therapeutic sleep-fat-reducing fat gasifying ointment for redically treating fat |
| 08/29/2007 | CN101024045A Special nutrient for tonifying middle aged and old men |
| 08/29/2007 | CN101024038A Medicine composition with fat-clearing, blood-pressure-reducing functions |